DuChemBIO Co.,Ltd.
Research DuChemBIO Co.,Ltd. (176750.KQ) on Bullrun: market cap KRW 244.05B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker176750.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 244.05B
- Financial periodQ2 2026
- RevenueKRW 11.20B
- Net incomeKRW 1.20B
- Free cash flowKRW 3.67B
- Gross margin35.9%
Valuation Snapshot
latest market cap is KRW 244.05B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 244.05B | n/a | n/a | n/a |
Dividend history
About DuChemBIO Co.,Ltd.
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is DuChemBIO Co.,Ltd.'s market cap?
DuChemBIO Co.,Ltd.'s market capitalization is KRW 244.05B.
What does DuChemBIO Co.,Ltd. do?
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease.